Technical Analysis for PRME - Prime Medicine, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| NR7-2 | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| MACD Bearish Signal Line Cross | Bearish | -0.31% | |
| 20 DMA Support | Bullish | -0.31% | |
| New Uptrend | Bullish | -0.31% | |
| NR7 | Range Contraction | -0.31% | |
| Wide Bands | Range Expansion | -0.31% | |
| New Downtrend | Bearish | -0.92% |
| Alert | Time |
|---|---|
| Possible NR7 | 1 day ago |
| Down 1% | 1 day ago |
| 60 Minute Opening Range Breakdown | 1 day ago |
| 1.5x Volume Pace | 1 day ago |
| Fell Below 20 DMA | 1 day ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/09/2024
Prime Medicine is a biotechnology company committed to delivering a new class of differentiated, one-time, curative genetic therapies to address the widest spectrum of diseases. The company is deploying Prime Editing technology, a versatile, precise, efficient and broad gene editing technology, which is designed to make only the right edit at the right position within a gene. With the theoretical potential to repair approximately 90 percent of known disease-causing genetic mutations across many organs and cell types, medicines based on Prime Editing, if approved, could offer a one-time curative genetic therapeutic option to a broad set of patients.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Disease Emerging Technologies Molecular Biology Medical Genetics Genetic Engineering Gene Editing Gene Editing Technology
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Disease Emerging Technologies Molecular Biology Medical Genetics Genetic Engineering Gene Editing Gene Editing Technology
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 17.195 |
| 52 Week Low | 4.11 |
| Average Volume | 840,195 |
| 200-Day Moving Average | 7.95 |
| 50-Day Moving Average | 6.00 |
| 20-Day Moving Average | 6.51 |
| 10-Day Moving Average | 7.00 |
| Average True Range | 0.56 |
| RSI (14) | 51.22 |
| ADX | 24.37 |
| +DI | 24.42 |
| -DI | 22.34 |
| Chandelier Exit (Long, 3 ATRs) | 6.59 |
| Chandelier Exit (Short, 3 ATRs) | 6.53 |
| Upper Bollinger Bands | 7.99 |
| Lower Bollinger Band | 5.02 |
| Percent B (%b) | 0.49 |
| BandWidth | 45.62 |
| MACD Line | 0.25 |
| MACD Signal Line | 0.31 |
| MACD Histogram | -0.0519 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 6.91 | ||||
| Resistance 3 (R3) | 6.92 | 6.79 | 6.84 | ||
| Resistance 2 (R2) | 6.79 | 6.68 | 6.79 | 6.81 | |
| Resistance 1 (R1) | 6.64 | 6.62 | 6.57 | 6.62 | 6.79 |
| Pivot Point | 6.51 | 6.51 | 6.48 | 6.50 | 6.51 |
| Support 1 (S1) | 6.35 | 6.40 | 6.29 | 6.34 | 6.17 |
| Support 2 (S2) | 6.22 | 6.33 | 6.22 | 6.15 | |
| Support 3 (S3) | 6.07 | 6.22 | 6.12 | ||
| Support 4 (S4) | 6.05 |
